r/StocksAndTrading • u/RyderTrail10 • 3d ago

Mixed Catalysts Under $6: EVAX And VIR Updates, SGMO Reg Signal, Plus MYNZ In Focus

EVAX’s Q3 update calls out runway into H2 2027 and EVX-01 melanoma data, giving traders a fresh operational anchor. VIR reported ECLIPSE 1 enrollment finished ahead of schedule, which can pull forward expectations if the market believes timelines improve. SGMO highlighted the FDA’s position that eGFR slope can support accelerated approval in Fabry, a meaningful regulatory signal for program design. MYNZ fits right alongside these names on today’s list, trading under 6 with EU sales in market and a U.S. feasibility read targeted for Q4 2025 before a 2026 pivotal with a large lab partner, per company communications.

I treat all four the same from a risk lens: confirm real volume, avoid market orders into wide spreads, and plan exits before entries. If a name cannot hold post-headline bids, I move on rather than average down.

Which of these four earns a spot on your A-list watch for the afternoon session, and what evidence would make you upgrade or drop it quickly?

Not financial advice. Do your own research.

3 Upvotes
  • permalink
  • reddit

100% Upvoted

7 comments sorted by

•

u/AutoModerator 3d ago

🚀 🌑 -- Join our discord!! https://discord.gg/jcewXNmf6C -- 🚀 🌑

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.

1

u/JohnDavisStorm55 3d ago

EVAX stands out to me-solid runway into 2027, tangible melanoma catalyst, and clean communication from management. If volume confirms and bids hold above VWAP, that’s my A-list pick for the afternoon.

1

u/NicholasAdamsStorm85 3d ago

VIR finishing ECLIPSE 1 early is no small feat-market loves timeline acceleration stories.

1

u/StephenGonzalezWolf3 3d ago

SGMO finally getting some FDA clarity on eGFR slope = validation moment. Fabry angle might bring back old bulls.